CZ20013307A3 - Farmaceutické kompozice obsahující komplexy kovů - Google Patents

Farmaceutické kompozice obsahující komplexy kovů Download PDF

Info

Publication number
CZ20013307A3
CZ20013307A3 CZ20013307A CZ20013307A CZ20013307A3 CZ 20013307 A3 CZ20013307 A3 CZ 20013307A3 CZ 20013307 A CZ20013307 A CZ 20013307A CZ 20013307 A CZ20013307 A CZ 20013307A CZ 20013307 A3 CZ20013307 A3 CZ 20013307A3
Authority
CZ
Czechia
Prior art keywords
bis
amd
ruthenium
methyl
complex
Prior art date
Application number
CZ20013307A
Other languages
Czech (cs)
English (en)
Inventor
Simon Fricker
Michael J. Abrams
Gary J. Bridger
Renato Skerlj
Ian Baird
Beth R. Cameron
Original Assignee
Anormed Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anormed Inc. filed Critical Anormed Inc.
Publication of CZ20013307A3 publication Critical patent/CZ20013307A3/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F19/00—Metal compounds according to more than one of main groups C07F1/00 - C07F17/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0046—Ruthenium compounds
    • C07F15/0053—Ruthenium compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CZ20013307A 1999-03-19 2000-03-17 Farmaceutické kompozice obsahující komplexy kovů CZ20013307A3 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12516699P 1999-03-19 1999-03-19

Publications (1)

Publication Number Publication Date
CZ20013307A3 true CZ20013307A3 (cs) 2002-05-15

Family

ID=22418482

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20013307A CZ20013307A3 (cs) 1999-03-19 2000-03-17 Farmaceutické kompozice obsahující komplexy kovů

Country Status (15)

Country Link
US (1) US20020049190A1 (enExample)
EP (1) EP1163247A1 (enExample)
JP (1) JP2004500321A (enExample)
KR (1) KR20010112343A (enExample)
CN (1) CN1391577A (enExample)
AU (1) AU3268500A (enExample)
BR (1) BR0011678A (enExample)
CA (1) CA2367282A1 (enExample)
CZ (1) CZ20013307A3 (enExample)
HU (1) HUP0400457A2 (enExample)
IL (1) IL145290A0 (enExample)
MX (1) MXPA01009410A (enExample)
NO (1) NO20014526L (enExample)
PL (1) PL356683A1 (enExample)
WO (1) WO2000056743A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ303156B6 (cs) 1999-04-13 2012-05-09 Anormed Inc. Komplex cisplatiny a zpusob jeho prípravy
JP4227701B2 (ja) * 1999-05-25 2009-02-18 中部キレスト株式会社 ジエチレントリアミン五酢酸ルテニウム二アンモニウム塩またはその水和物およびその製法
US6489638B2 (en) * 2000-06-23 2002-12-03 Semiconductor Energy Laboratory Co., Ltd. Light emitting device
US6894049B1 (en) 2000-10-04 2005-05-17 Anormed, Inc. Platinum complexes as antitumor agents
US20020072512A1 (en) * 2000-12-08 2002-06-13 Metaphore Pharmaceuticals, Inc Method of preventing and treating HIV-mediated central nervous system damage
GB0111872D0 (en) 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
EP2319518A1 (en) 2002-02-04 2011-05-11 ALFAMA-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda. Use of CO-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases
GB2395431A (en) * 2002-11-20 2004-05-26 Northwick Park Inst For Medica Combination of a metal carbonyl compound and a guanylate cyclase stimulant or stabilizer for the therapeutic delivery of carbon monoxide
GB2395432B (en) * 2002-11-20 2005-09-14 Northwick Park Inst For Medica Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs
ES2390457T3 (es) * 2003-08-04 2012-11-13 Johnson & Johnson Consumer Companies, Inc. Métodos para el tratamiento de enfermedades dermatológicas
EP1712547B1 (en) 2004-02-05 2011-12-14 Kyorin Pharmaceutical Co., Ltd. Bicycloester derivative
FR2873037B1 (fr) * 2004-07-13 2008-04-11 Univ Pasteur Methodes et compositions pour le traitement de cancers
WO2007072018A2 (en) * 2005-12-21 2007-06-28 Oxford Biosensors Ltd Redox mediators
GB0601394D0 (en) 2006-01-24 2006-03-01 Hemocorm Ltd Therapeutic delivery of carbon monoxide
CA2645154C (en) 2006-03-08 2011-11-29 Kyorin Pharmaceutical Co., Ltd. Method for producing aminoacetylpyrrolidinecarbonitrile derivative and production intermediate thereof
EP2032701B1 (en) * 2006-06-23 2013-11-27 Alethia Biotherapeutics Inc. Polynucleotides and polypeptides involved in cancer
WO2008038305A2 (en) * 2006-09-26 2008-04-03 Jegannathan Srinivas Therapeutical formulation comprising a thiazolidinedione and a nitric oxide scavenger.
JPWO2008114857A1 (ja) 2007-03-22 2010-07-08 杏林製薬株式会社 アミノアセチルピロリジンカルボニトリル誘導体の製造方法
NZ592432A (en) 2008-11-03 2013-01-25 Alethia Biotherapeutics Inc Antibodies that specifically block the biological activity of a tumor antigen Kidney associated antigen 1 (KAAG1)
DE102010014412A1 (de) 2010-04-08 2012-04-19 Friedrich-Schiller-Universität Jena Verwendung von zweikernigen Eisenkomplexen mit schwefelhaltigen Liganden als pharmakologische Wirkstoffe
DE102010014411A1 (de) 2010-04-08 2011-10-13 Friedrich-Schiller-Universität Jena Kohlenmonoxid und Eisen freisetzende Moleküle, deren Verwendung und Verfahren zu deren Herstellung
PT3173427T (pt) 2011-03-31 2019-09-17 Adc Therapeutics Sa Anticorpos contra antigénio associado ao rim 1 e fragmentos de ligação a antigénio dos mesmos
JP5978291B2 (ja) 2011-04-19 2016-08-24 アルファーマ インコーポレイテッドＡｌｆａｍａ，Ｉｎｃ． 一酸化炭素放出分子およびその使用
JP6134710B2 (ja) 2011-07-21 2017-05-24 アルファーマ インコーポレイテッドＡｌｆａｍａ，Ｉｎｃ． 一酸化ルテニウム放出分子およびその使用
PT2802351T (pt) 2012-01-09 2019-06-27 Adc Therapeutics Sa Agentes para o tratamento de cancro da mama triplo negativo
DE102012004132A1 (de) 2012-02-29 2013-08-29 Friedrich-Schiller-Universität Jena Kohlenstoffmonoxid freisetzende Materialien und deren Verwendung
DE102014008537A1 (de) 2014-06-04 2015-12-17 Friedrich-Schiller-Universität Jena Wasserlösliche manganbasierte Kohlenstoffmonoxid freisetzende Moleküle, deren Verwendung und Verfahren zu deren Herstellung
EP3212610B1 (en) * 2014-10-30 2020-10-28 Katholieke Universiteit Leuven Methods for low temperature fluorine-18 radiolabeling of biomolecules
CN113429456B (zh) * 2021-06-11 2022-05-31 首都医科大学 多肽衍生物钌类络合物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112974A (en) * 1985-01-18 1992-05-12 The Trustees Of Columbia University In The City Of New York Mixed ligand complexes and uses thereof as binding agents to DNA
US4721669A (en) * 1985-01-18 1988-01-26 The Trustees Of Columbia University In The City Of New York Chemical probes for left-handed DNA and chiral metal complexes as Z-specific anti-tumor agents
GB9317686D0 (en) * 1993-08-25 1993-10-13 Johnson Matthey Plc Pharmaceutical compositions
SE9703396D0 (sv) * 1997-09-19 1997-09-19 Lincoln Binuclear complex

Also Published As

Publication number Publication date
NO20014526D0 (no) 2001-09-18
MXPA01009410A (es) 2003-06-06
IL145290A0 (en) 2002-06-30
BR0011678A (pt) 2002-02-26
KR20010112343A (ko) 2001-12-20
NO20014526L (no) 2001-10-16
CN1391577A (zh) 2003-01-15
WO2000056743A1 (en) 2000-09-28
CA2367282A1 (en) 2000-09-28
HUP0400457A2 (hu) 2004-05-28
US20020049190A1 (en) 2002-04-25
PL356683A1 (en) 2004-06-28
AU3268500A (en) 2000-10-09
EP1163247A1 (en) 2001-12-19
JP2004500321A (ja) 2004-01-08

Similar Documents

Publication Publication Date Title
CZ20013307A3 (cs) Farmaceutické kompozice obsahující komplexy kovů
US5824673A (en) Pharmaceutical compositions comprising metal complexes
US6417182B1 (en) Pharmaceutical compositions comprising metal complexes
Chen et al. A ruthenium (II) β-carboline complex induced p53-mediated apoptosis in cancer cells
EP2016085B9 (en) Transition metal complexes for inhibiting resistance in the treatment of cancer and metastasis
Mészáros et al. An 8-hydroxyquinoline–proline hybrid with multidrug resistance reversal activity and the solution chemistry of its half-sandwich organometallic Ru and Rh complexes
JP6316479B2 (ja) カルマンガホジピル、新たな化学実体、および他の混合金属錯体、調製の方法、組成物、および処置の方法
Poljarević et al. Comparative solution equilibrium and structural studies of half-sandwich ruthenium (II)(η6-toluene) complexes of picolinate derivatives
Lovison et al. Cationic carboxylate and thioacetate ruthenium (II) complexes: synthesis and cytotoxic activity against anaplastic thyroid cancer cells
Wang et al. Cycloplatinated (II) complex based on isoquinoline alkaloid elicits ferritinophagy-dependent ferroptosis in triple-negative breast cancer cells
Mathuber et al. Development of a cobalt (III)-based ponatinib prodrug system
Riedl et al. N-and S-donor leaving groups in triazole-based ruthena (ii) cycles: potent anticancer activity, selective activation, and mode of action studies
JP2005501859A (ja) 白金錯体及びガンの処置におけるそれらの使用
Sharkawy et al. A novel benzothiazole-1, 2, 3-triazole-based arene osmium (II) complex as an effective rhabdomyosarcoma cancer stem cell agent
Mansour et al. A comprehensive survey of cytotoxic active half-sandwich Ir (iii) complexes: structural perspective, and mechanism of action
Lu et al. Increasing the cytotoxicity of Ru (II) polypyridyl complexes by tuning the electron-donating ability of 1, 10-phenanthroline ligands
US20090175775A1 (en) Metal complexes having vitamin b12 as a ligand
Richter et al. Platinum (II/IV) complexes with N-substituted carboxylate ethylenediamine/propylenediamine ligands: preparation, characterization and in vitro activity
Radanovic et al. Synthesis and characterization of hexadentate cobalt (III) complexes with novel edta-type ligands. 1. Circular dichroism of a cobalt (III) complex of ethylenediamine-N-acetic-N, N', N'-tri-3-propionic acid
CN114920728B (zh) 一种甲异靛衍生物及其制备方法与应用
WO2025108479A1 (en) Compounds for degradation or inhibition of kras mutant proteins and uses thereof
Icsel et al. Trans-Pd (II) and Pt (II) saccharinate complexes with S, S-diphenylsulfimide: Synthesis, structures, anticancer evaluation and molecular docking
Saha Design, Synthesis and Bio-Evaluation of Anticancer Ruthenium (II) Complexes with Applications in Photoactivated Chemotherapy and Chemotherapy
CZ2023360A3 (cs) Koordinační sloučeniny ruthenia a osmia pro použití pro léčbu plicních nádorových onemocnění
Fortney Ligands Designed for Ruthenium Nitrosyl Transport